Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Janssen Research & Development, LLC
Janssen Research & Development, LLC
City of Hope Medical Center
Fate Therapeutics
Hutchmed
Ohio State University Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Alabama at Birmingham
National Cancer Institute (NCI)
Zenith Epigenetics
Barbara Ann Karmanos Cancer Institute
Bristol-Myers Squibb